Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer

Chemotherapy combined with the angiogenesis inhibitor bevacizumab (BVZ) is approved as a first-line treatment in metastatic colorectal cancer (mCRC). Limited clinical benefit underpins the need for improved understanding of resistance mechanisms and the elucidation of novel predictive biomarkers. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Barat, Ana, Smeets, Dominiek, Moran, Bruce, Zhang, Wu, Cao, Shu, Das, Sudipto, Klinger, Rut, Betge, Johannes, Murphy, Verena, Bacon, Orna, Kay, Elaine W., Van Grieken, Nicole C. T., Verheul, Henk M. W., Gaiser, Timo, Schulte, Nadine, Ebert, Matthias P., Fender, Bozena, Hennessy, Bryan T., McNamara, Deborah A., O’Connor, Darran, Gallagher, William M., Cremolini, Chiara, Loupakis, Fotios, Parikh, Aparna, Mancao, Christoph, Ylstra, Bauke, Lambrechts, Diether, Lenz, Heinz-Josef, Byrne, Annette T., Prehn, Jochen H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299973/
https://www.ncbi.nlm.nih.gov/pubmed/32555399
http://dx.doi.org/10.1038/s41598-020-65869-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299973/
https://www.ncbi.nlm.nih.gov/pubmed/32555399
http://dx.doi.org/10.1038/s41598-020-65869-2

Ejemplares similares